How this BLSH vs CORZ comparison is calculated

All metrics are based on trailing twelve months (TTM) financial data, consensus analyst estimates, and standardized valuation ratios. Data is sourced from Financial Modeling Prep and SEC EDGAR. Figures are normalized to ensure a fair comparison between Bullish and Core Scientific, Inc.. Analyst price targets and ratings are aggregated from Wall Street consensus as of 2026-05-19.

Quick verdict: Bullish vs Core Scientific, Inc. in 2026

Bullish emerges as the growth leader, showcasing a less severe revenue decline compared to its peer. Core Scientific, Inc., however, claims the valuation edge with more attractive multiples and a less negative DCF upside. When examining operational efficiency, BLSH leads on net margin and free cash flow generation, while CORZ is the clear analyst favorite with a higher percentage of buy ratings. Nonetheless, Bullish stock currently offers the most significant potential upside based on analyst price targets. Not investment advice.

Bullish vs Core Scientific, Inc.: key metrics side by side

A full side-by-side look at Bullish (BLSH) and Core Scientific, Inc. (CORZ) across earnings multiples, profitability, revenue momentum, and analyst sentiment — data updated 2026-05-19.

Relative valuation: BLSH vs CORZ

When assessing the fundamental discount, Core Scientific, Inc. appears to offer a more compelling relative valuation compared to Bullish based on several key metrics. CORZ trades at an earnings multiple of -6.26x, which, while negative, represents a slightly deeper “discount” than BLSH’s P/E of -5.36x. Similarly, Core Scientific, Inc. exhibits a price-to-book ratio of -5.83x against Bullish’s 2.03x, indicating a substantially lower valuation from a book value perspective, albeit one that requires careful interpretation given the negative value.

Furthermore, the discounted cash flow (DCF) analysis suggests a less severe undervaluation for Core Scientific, Inc., with an estimated upside of -120.0%, significantly better than Bullish’s staggering -500439.5%. This considerable divergence in projected intrinsic value implies that CORZ might present a more attractive entry point for value-oriented investors, based on current consensus data. The negative multiples for both companies underscore that neither is currently profitable on a trailing twelve-month basis, making traditional valuation challenging, but Core Scientific, Inc. shows a quantitative edge in these specific comparisons.

Revenue momentum: Bullish vs Core Scientific, Inc.

Examining the topline expansion of these two technology firms reveals a nuanced picture. Bullish (BLSH) recorded a year-over-year revenue growth of -2.1%, indicating a modest contraction in its top line. In contrast, Core Scientific, Inc. (CORZ) faced a more substantial decline, with its revenue decreasing by -37.5% over the same period. This suggests that BLSH has demonstrated greater resilience in maintaining its revenue base, or at least experiencing a less severe downturn in its sales trajectory. Despite the negative growth rates for both companies, Bullish shows a relative strength in preserving its revenue stream.

However, the operational efficiency metrics present a different story. Core Scientific, Inc. boasts a robust EBITDA margin of 25.09%, highlighting its ability to generate significant earnings before interest, taxes, depreciation, and amortization from its sales. Bullish, on the other hand, recorded an EBITDA margin of -0.21%, indicating that its operations are not yet generating positive EBITDA. While BLSH exhibits better revenue stability, CORZ demonstrates a much stronger underlying profitability structure when it does generate sales. Investors must weigh the current revenue trends against the operational leverage, noting that this gap in operational profitability may not persist if market conditions or strategic initiatives dramatically alter either company’s performance.

Profitability and cash generation: BLSH vs CORZ

In terms of bottom-line performance, Bullish exhibits a significantly stronger position than Core Scientific, Inc. BLSH reported a net margin of -0.46%, which, while negative, is dramatically better than CORZ’s deeply negative net margin of -342.93%. This stark contrast indicates that Bullish is much closer to achieving profitability, with its expenses almost matching its substantial revenue base of $244.97 billion. Core Scientific, Inc., with its revenue of $319,019,000, faces considerable challenges in controlling costs relative to its sales.

When considering cash conversion, Bullish once again shows superiority with a positive free cash flow (FCF) yield of 0.83%. This means that BLSH is generating cash from its operations relative to its market capitalization, a positive sign for its financial health and potential for future investments or debt reduction. Conversely, Core Scientific, Inc. recorded a negative FCF yield of -6.29%, suggesting it is consuming cash rather than generating it. Both companies show N/A% for return on equity (ROE), indicating insufficient or fluctuating equity to calculate a meaningful return, which is not uncommon for companies in their current growth or restructuring phases. Overall, Bullish demonstrates a more favorable profile in both net profitability and ability to generate free cash flow.

Wall Street view: Bullish vs Core Scientific, Inc. analyst ratings

The sentiment from Wall Street analysts for both Bullish and Core Scientific, Inc. is largely positive, with both companies receiving a consensus “Buy” rating. However, a deeper dive into the specific metrics reveals some interesting distinctions. Bullish stock has garnered coverage from 7 analysts, with 71.4% issuing a “Buy” recommendation. These analysts have set a consensus price target of $51 for BLSH, implying a substantial upside potential of +43.4% from its current trading price. This indicates a strong belief in the company’s future growth and valuation appreciation by a majority of its covering analysts.

Core Scientific, Inc., meanwhile, benefits from broader analyst coverage, with 22 analysts weighing in on its prospects. A higher percentage of these analysts, 86.4%, recommend a “Buy” for CORZ, suggesting a slightly stronger conviction within the analyst community compared to Bullish. The consensus target price for Core Scientific, Inc. is $31.6, which represents an upside of +34.1%. While CORZ enjoys higher analyst buy-side consensus, Bullish stock currently offers a greater potential percentage increase to its target price. It’s important to remember that these targets may vary depending on future estimate revisions and market dynamics.

Which investor profile fits BLSH vs CORZ?

For the **growth investor**, the choice between Bullish and Core Scientific, Inc. presents a mixed bag, though BLSH might slightly edge out based on current revenue trends. Bullish (BLSH) recorded a year-over-year revenue contraction of -2.1%, which is less severe than Core Scientific, Inc.’s (CORZ) -37.5%. This suggests a comparatively more stable top-line performance for Bullish. However, CORZ’s impressive EBITDA margin of 25.09% far surpasses BLSH’s -0.21%, indicating a much stronger operational foundation when Core Scientific, Inc. does generate revenue. A growth investor must weigh the relative stability of BLSH’s revenue against the operational leverage and efficiency shown by CORZ, recognizing the potential for significant recovery or expansion in a more favorable market for Core Scientific, Inc.

The **value investor** looking for deep discounts and potential turnarounds might find Core Scientific, Inc. more intriguing, albeit with higher inherent risk. CORZ trades at a P/E of -6.26x and a P/B of -5.83x, both significantly more negative than Bullish’s P/E of -5.36x and P/B of 2.03x. While negative multiples signify current unprofitability, from a purely quantitative standpoint, these suggest a more substantial “discount” or perceived undervaluation for Core Scientific, Inc. on a trailing twelve-month basis. Furthermore, CORZ’s DCF upside of -120.0% is considerably less negative than Bullish’s -500439.5%, indicating a more palatable intrinsic value outlook. This suggests that if a turnaround is anticipated, the potential upside from a deeply discounted base could be greater for CORZ.

For the **income investor**, neither Bullish nor Core Scientific, Inc. currently offers an attractive proposition. Both BLSH and CORZ maintain a dividend yield of 0%, meaning they do not distribute earnings to shareholders in the form of regular dividends. This is common for technology companies, especially those in growth or restructuring phases, where capital is typically reinvested back into the business. Therefore, investors prioritizing current income streams should look elsewhere. This is not investment advice. Always do your own research.

More Bullish and Core Scientific, Inc. comparisons

Bullish (BLSH) full stock analysis · Core Scientific, Inc. (CORZ) full stock analysis · All stock comparisons